SciELO - Scientific Electronic Library Online

vol.41 issue3The reason for having a code of pharmaceutical ethics: Spanish Pharmacists Code of Ethics author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google


Farmacia Hospitalaria

On-line version ISSN 2171-8695Print version ISSN 1130-6343


MAESTRO NOMBELA, Almudena et al. Mirabegron, a breakthrough in overactive bladder syndrome?. Farm Hosp. [online]. 2017, vol.41, n.3, pp.410-422. ISSN 2171-8695.


Overactive bladder syndrome is a condition with high prevalence, which has a negative impact on patients’ quality of life. A drug with a novel mechanism of action has been recently approved: mirabegron. The objective of this study is to review the scientific evidence available on mirabegron, with the aim to analyze its efficacy, safety and cost, and thus estimate its role within current pharmacotherapy.


The effectiveness and safety of mirabegron were analyzed through an evaluation of scientific evidence. The cost of different pharmacological alternatives was calculated based on their Defined Daily Dose (DDD) and their manufacturer’s sale price.


The use of mirabegron in the treatment of overactive bladder syndrome is supported by three randomized clinical trials, controlled with placebo, at 12 weeks. All three share the same primary efficacy variables (number of incontinence episodes per 24 hours and number of micturitions per 24 hours). Long-term efficacy data are based on a 12-month study, where efficacy outcomes were measured as secondary variables. In all studies, mirabegron showed a significant but modest effect. Some of the most frequently detected adverse effects were: hypertension, increase of glucose in blood, headache, urinary tract infections, constipation and tachycardia. Special attention must be paid to cardiovascular events.


The clinical efficacy of mirabegron is very modest and comparable to that achieved with the other drugs approved for this indication. Moreover, it is more expensive than other therapeutic options. Cardiac risks and urinary infections only allow to consider it as an alternative option to anticholinergic drugs, when these are contraindicated, show no clinical efficacy, or cause unacceptable adverse effects.

Keywords : Mirabegron; Overactive bladder syndrome; Selective β3-adrenoceptor agonist; Efficacy; Evidence; Safety.

        · abstract in Spanish     · text in English | Spanish     · English ( pdf )